661 related articles for article (PubMed ID: 26212075)
1. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
[TBL] [Abstract][Full Text] [Related]
2. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
[TBL] [Abstract][Full Text] [Related]
3. Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS.
Nielsen MJ; Lehmann J; Leeming DJ; Schierwagen R; Klein S; Jansen C; Strassburg CP; Bendtsen F; Møller S; Sauerbruch T; Karsdal MA; Krag A; Trebicka J
Dig Dis Sci; 2015 Nov; 60(11):3456-64. PubMed ID: 26138655
[TBL] [Abstract][Full Text] [Related]
4. Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality.
Lehmann JM; Claus K; Jansen C; Pohlmann A; Schierwagen R; Meyer C; Thomas D; Manekeller S; Claria J; Strassburg CP; Trautwein C; Wasmuth HE; Berres ML; Trebicka J
Liver Int; 2018 May; 38(5):875-884. PubMed ID: 29105936
[TBL] [Abstract][Full Text] [Related]
5. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.
Qiu B; Zhao MF; Yue ZD; Zhao HW; Wang L; Fan ZH; He FL; Dai S; Yao JN; Liu FQ
World J Gastroenterol; 2015 Nov; 21(43):12439-47. PubMed ID: 26604651
[TBL] [Abstract][Full Text] [Related]
6. Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt.
Bai M; He CY; Qi XS; Yin ZX; Wang JH; Guo WG; Niu J; Xia JL; Zhang ZL; Larson AC; Wu KC; Fan DM; Han GH
World J Gastroenterol; 2014 Jan; 20(3):774-85. PubMed ID: 24574750
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.
Yao J; Zuo L; An G; Yue Z; Zhao H; Wang L; Liu F
J Gastrointestin Liver Dis; 2015 Sep; 24(3):301-7. PubMed ID: 26405702
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.
Teng D; Zuo H; Liu L; Dong J; Ding L
Virol J; 2018 Oct; 15(1):151. PubMed ID: 30285813
[TBL] [Abstract][Full Text] [Related]
9. Transjugular intrahepatic portosystemic shunt creation for cirrhotic portal hypertension is well tolerated among patients with portal vein thrombosis.
Merola J; Fortune BE; Deng Y; Ciarleglio M; Amirbekian S; Chaudhary N; Shanbhogue A; Ayyagari R; Rodriguez-Davalos MI; Teperman L; Charles HW; Sigal SH
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):668-675. PubMed ID: 29462027
[TBL] [Abstract][Full Text] [Related]
10. Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy.
Deng D; Liao MS; Qin JP; Li XA
Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):232-6. PubMed ID: 16698582
[TBL] [Abstract][Full Text] [Related]
11. The role of miRNA-34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS.
Jansen C; Eischeid H; Goertzen J; Schierwagen R; Anadol E; Strassburg CP; Sauerbruch T; Odenthal M; Trebicka J
PLoS One; 2014; 9(7):e103779. PubMed ID: 25068403
[TBL] [Abstract][Full Text] [Related]
12. Transjugular intrahepatic portosystemic shunt as a bridge to non-hepatic surgery in cirrhotic patients with severe portal hypertension: a systematic review.
Lahat E; Lim C; Bhangui P; Fuentes L; Osseis M; Moussallem T; Salloum C; Azoulay D
HPB (Oxford); 2018 Feb; 20(2):101-109. PubMed ID: 29110990
[TBL] [Abstract][Full Text] [Related]
13. Bayesian network-based survival prediction model for patients having undergone post-transjugular intrahepatic portosystemic shunt for portal hypertension.
Chen R; Luo L; Zhang YZ; Liu Z; Liu AL; Zhang YW
World J Gastroenterol; 2024 Apr; 30(13):1859-1870. PubMed ID: 38659484
[TBL] [Abstract][Full Text] [Related]
14. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience.
Lodato F; Berzigotti A; Lisotti A; Azzaroli F; Mosconi C; Giampalma E; Renzulli M; Cappelli A; Buonfiglioli F; Calvanese C; Zoli M; Golfieri R; Mazzella G
Scand J Gastroenterol; 2012 Dec; 47(12):1494-500. PubMed ID: 22958120
[TBL] [Abstract][Full Text] [Related]
15. Effect of technical parameters on transjugular intrahepatic portosystemic shunts utilizing stent grafts.
Andring B; Kalva SP; Sutphin P; Srinivasa R; Anene A; Burrell M; Xi Y; Pillai AK
World J Gastroenterol; 2015 Jul; 21(26):8110-7. PubMed ID: 26185383
[TBL] [Abstract][Full Text] [Related]
16. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
Dissegna D; Sponza M; Falleti E; Fabris C; Vit A; Angeli P; Piano S; Cussigh A; Cmet S; Toniutto P
Eur J Gastroenterol Hepatol; 2019 May; 31(5):626-632. PubMed ID: 30550458
[TBL] [Abstract][Full Text] [Related]
17. APTR is a prognostic marker in cirrhotic patients with portal hypertension during TIPS procedure.
Yu S; Qi Y; Jiang J; Wang H; Zhou Q
Gene; 2018 Mar; 645():30-33. PubMed ID: 29274906
[TBL] [Abstract][Full Text] [Related]
18. Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension.
Trebicka J; Krag A; Gansweid S; Schiedermaier P; Strunk HM; Fimmers R; Strassburg CP; Bendtsen F; Møller S; Sauerbruch T; Spengler U
PLoS One; 2013; 8(12):e83341. PubMed ID: 24386183
[TBL] [Abstract][Full Text] [Related]
19. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis.
Han G; Qi X; He C; Yin Z; Wang J; Xia J; Yang Z; Bai M; Meng X; Niu J; Wu K; Fan D
J Hepatol; 2011 Jan; 54(1):78-88. PubMed ID: 20932597
[TBL] [Abstract][Full Text] [Related]
20. Does Transjugular Intrahepatic Portosystemic Shunt Stent Differentially Improve Survival in a Subset of Cirrhotic Patients?
Trebicka J
Semin Liver Dis; 2018 Feb; 38(1):87-96. PubMed ID: 29471569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
